## Data Sheet (Cat.No.T16906)




### Sograzepide

## **Chemical Properties**

CAS No.: 155488-25-8 Formula: C28H30N6O3

Molecular Weight: 498.58 Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).



# **Biological Description**

| Description                | Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively).  |
|----------------------------|---|
| Targets(IC <sub>50</sub> ) | Gastrin/CCK-B: 0.1 nM<br>Gastrin/CCK-A: 501 nM  |
| In vivo                    | Sograzepide (0.1 $\mu$ mol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anesthetized rats (ED50: 87 nmol/kg). Sograzepide (intravenous injection; 10 $\mu$ M/kg) inhibits pentagastrin-induced acid secretion (ED50: 0.0086 $\mu$ M/kg). Sograzepide (intravenous injection; p.o.) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner (ED50: 0.018 and 0.020 $\mu$ M/kg, respectively) [1][2]. |

# **Solubility Information**

| Solubility | DMSO: 100 mg/mL (200.57 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|
|            | (< 1 mg/m releas to the product slightly soluble of misoluble)                              |

#### **Preparing Stock Solutions**

|       | 1mg      | 5mg       | 10mg      |
|-------|----------|-----------|-----------|
| 1 mM  | 2.006 mL | 10.028 mL | 20.057 mL |
| 5 mM  | 0.401 mL | 2.006 mL  | 4.011 mL  |
| 10 mM | 0.201 mL | 1.003 mL  | 2.006 mL  |
| 50 mM | 0.04 mL  | 0.201 mL  | 0.401 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: -  $80 \,^{\circ}$ C for 6 months; -  $20 \,^{\circ}$ C for 1 month. Please use it as soon as possible.

#### Reference

- 1. Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55.
- 2. Takinami Y, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther. 1997 Feb;11(1):113-20.

Page 1 of 2 www.targetmol.com

### Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only  $\cdot$  Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com